Jon Stacks’ Post

Still have no idea what "neurotyping" means? Fret no more! Check out this great interview with Universal Brain CEO, Kazu Okuda, MD, to learn more about how functional biomarkers can be used to improve the treatment of depression.

We emphasize the importance of integrating brain function measures into psychiatric practice. I often explain Universal Brain replicates the expertise of top-notch professional psychiatrists through our innovative EEG/ERP product. Just as psychiatrists assess a patient's brain function(in this case emotional reactivity etc...) through conversation to differentiate between typical and atypical depression and determine the best treatment options(SSRI, MAOIs, or could be CBT), we measure each brain function directly using ERP. Our approach provides data-driven insights to suggest the most effective treatment options, enhancing the precision and outcomes of psychiatric care. #depression #precisionpsychiatry #biotyping

Our Founder & CEO, Kazu Okuda, MD had the chance to share about the advancements of precision psychiatry, the role of objective brain data, the future of mental healthcare. Have a read!

In collaboration with STALICLA, clinical Phase 1 trials are being led by Drs. Suchitra Krishnan-sarin, John Krystal and Stephanie O'Malley from the Department of Psychiatry of the Yale University School of Medicine under a center grant from the National Institute on Alcohol Abuse and Alcoholism. One of the studies aims to conduct a comprehensive examination of the influence of STP7 (Mavoglurant) on alcohol drinking behaviors among heavy drinkers. The study will also assess the potential of mavoglurant as a treatment candidate to benefit patients affected by Alcohol Use Disorder. Under the agreement, STALICLA will provide STP7 (Mavoglurant) to the principal investigator of the NIAAA center, Dr. John Krystal. Dr. Krystal is a leading expert in the areas of substance use disorders, post-traumatic stress disorder, schizophrenia, and depression, and is currently Chair of the Department of Psychiatry of the Yale University School of Medicine. #Stalicla #Neurology #Innovation #Biotechnology #CNS #precisionmedicine #neuropsychiatry

🔬 A New Era in Psychiatry: The REALMENT Project 🧠 In an exclusive interview, Ole Andreassen, a leading figure in the field of psychiatry and Director of the Centre of Excellence NORMEN, shares how the #REALMENT project contributes to the development of personalised medicine in psychiatry. 📈 Key Goals Utilise Real World Data (#RWD) & #AI for tailored treatments Develop predictive algorithms for medication efficacy and side-effects 👩⚕️ Implications Clinicians can make data-driven decisions Patients benefit from more #precise, #effective treatments 🔗 Find out more: https://bit.ly/3FtBqBE #MentalHealth #Realment

As an editor of the Frontiers in Psychiatry (SCI 4.2), I am pleased that we have published a special issue on Case Reports in Psychopharmacology. This was a very successful collection with 22 accepted manuscripts. The eBook has recently been published online and can be found on the research topic page - the collection has already received over 49,000 total views and downloads. We have described several important topics, such as adverse events, interactions, comorbidities and collaboration with clinical pharmacists in psychiatry. We closed this issue with the manuscript describing the benefits of clinical pharmacists' interventions in a psychiatric hospital. Thanks to all reviewers and colleagues- psychiatrists, pharmacists and researchers for your papers. #Psychiatry #Clinical Pharmacy

🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters

🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters

#transcript Dr. Kazu Okuda, Founder CEO of Universal Brain, uses neurotyping based on EEG data to better understand the different types of depression & deliver more precise treatments. To facilitate the availability of EEG data, Universal Brain has developed a next-generation EEG headset that is affordable & comfortable. The headset allows for the collection of data that can be used to analyze neural profiles of patients & tailor treatments. This precision psychiatry approach is the future of depression treatment & for identifying early warning signs of depression in the younger population. #UniversalBrain #Neurotyping #BrainBiomarkers #Depression #PrecisionPsychiatry universal-brain.com https://lnkd.in/gNcDU2bm

Next lecture on Philosophy & Psychiatry Seminar (Institut društvenih nauka - Institute of Social Sciences): “The Drug Worked for Me” … But Did It? Jacob Stegenga (with Hamed Tabatabaei Ghomi) In his presentation, Dr Jacob Stegenga will question whether inferences from patients' first-person experiences about the effectiveness of their prescribed psychiatric drugs are reliable. Join us on April 18, 11.00 CET! 🙂 https://lnkd.in/dXymfvE5